Newsletters
What's Happening at American Gene™
Our team personally cares about the people we serve. We make progress every day to end suffering and premature death from serious human diseases. The Newsletter is one quick way to keep track of AGT™ advancements on all its programs and other events happening at the company. We look forward to keeping you up to date on our mission.
Newsletters
What's Happening at American Gene™
Our team personally cares about the people we serve. We make progress every day to end suffering and premature death from serious human diseases. The Newsletter is one quick way to keep track of AGT™ advancements on all its programs and other events happening at the company. We look forward to keeping you up to date on our mission.
NEWSLETTER VOLUME 8
AGT’s HIV cure program is nearing a major milestone: Investigational New Drug (IND) submission. The IND is the key document that reports the safety data the FDA requires prior to a human trial. If the document meets the expected criteria, AGT will be authorized to…
Read More
NEWSLETTER VOLUME 7
In wrapping up the year, AGT was proud to be featured as a State of Maryland “Success Story” for its growth in Maryland and achievements in the gene and cell therapy industry. Watch The Video 2018 has been a great year for American Gene Technologies:…
Read More
NEWSLETTER VOLUME 6
AGT’s progress over the first half of 2018 has been tremendous: six patents granted, major advances in all of its key projects: HIV, PKU and immuno-oncology, substantial momentum on social media with constant activity and announcements to thousands of followers, and huge growth in business development activities through outreach,…
Read More
NEWSLETTER VOLUME 5
AGT is in position for key milestones and success in 2018. 2017 brought attention to the industry and particularly to AGT. We raised nearly $8M (approximately double the previous year), and efficiently leveraged the capital to advance AGT’s key technologies and pre-clinical programs. Our recent…
Read More
NEWSLETTER VOLUME 4
American Gene Technologies International CEO, Jeff Galvin, is increasingly in demand for his thought leadership in addition to his vision for AGT. Jeff was invited to deliver the closing presentation at the June 13th HIMSS Precision Medicine Summit in Boston. He was also invited to…
Read More
NEWSLETTER VOLUME 3
C. Neil Lyons AGT is announcing the appointment of C. Neil Lyons as Executive Vice President and Chief Financial Officer. Neil brings more than 30 years of experience in finance, strategy, capital, SEC compliance, and corporate governance in both public and private companies, and spent…
Read More
NEWSLETTER VOLUME 2
AGT and GeoVax Labs Inc. (OTCQB: GOVX) have announced a collaboration in preparation for a phase 1 clinical trial to test AGT’s HIV cure. This is the first announcement of several collaborations that will support testing the safety and feasibility of genetically modified CD4+T cells…
Read More
NEWSLETTER VOLUME 1
We’ve kicked off 2017 with new intensity and excitement! AGT will be submitting our first Investigational New Drug (IND) application consistent with FDA’s great reception and feedback on our pre-IND application in November. We are on course to become a clinical stage biotech company in…
Read More- « Previous
- 1
- 2
Subscribe to Our Newsletter
Subscribe to our newsletter to keep up to date with all the latest news about American Gene Technologies!
Follow AGT on Social Media
AGT on Facebook
Nick Tressler, MBA | People on The Move - Washington Business Journal
bit.ly
Nick Tressler, MBA Hired at Addimmune™ / American Gene Technologies®
